REGN Dec 2025 360.000 put
| Previous close | 4.7900 |
| Open | 4.7900 |
| Bid | 0.0000 |
| Ask | 9.6000 |
| Strike | 360.00 |
| Expiry date | 2025-12-19 |
| Day's range | 4.7900 - 4.7900 |
| Contract range | N/A |
| Volume | |
| Open interest | 6 |
GlobeNewswireDupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNP Current treatment options leave many patients with uncontrolled disease and often result in the recurrence of nasal polyps Dupixent is the leading biologic medicine for all five FDA-approved indications in new-to-brand prescriptions TARRYTOWN, N.Y. and PARIS, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the
ZacksPharma Stock Roundup: FDA Approves J&J's Tremfya for Ulcerative Colitis & More
FDA approves J&J's Tremfya for ulcerative colitis. NVO's oral obesity pill, amycretin, shows faster weight loss than weekly injection, Wegovy.
ZacksSanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study Goals
This is the second pivotal late-stage study on SNY/REGN's Dupixent in chronic spontaneous urticaria indication to meet primary and key secondary endpoints.
